Drugs / SER-109
SER-109
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02437487 | May 2015 → Jul 2016 | Clostridium difficile colitis | Seres Therapeutics, Inc. | Completed | Missed primary |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT03183141 | Oct 2017 → Apr 2022 | Clostridium difficile colitis | Seres Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03183128 | Jul 2017 → Jul 2020 | Clostridium difficile colitis | Seres Therapeutics, Inc. | Completed | Met primary |
| Phase not stated1 trial | ||||||
| — | NCT02437500 | — | Clostridium difficile colitis | Seres Therapeutics, Inc. | Approved for marketing | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SER-109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03183141 ↗ |
| Known as | fecal microbiota spores, live-brpk | “VOWST (VOWST oral spores, VOS; fecal microbiota spores, live-brpk, formerly SER-109) is an FDA-approved, orally administered consortium of purified Firmicutes spores developed...” PMID 41491103 ↗ Jan 2026 |
| Known as | VOS | “VOWST (VOWST oral spores, VOS; fecal microbiota spores, live-brpk, formerly SER-109) is an FDA-approved, orally administered consortium of purified Firmicutes spores developed...” PMID 41491103 ↗ Jan 20261“VOWST oral spores (VOS, previously SER-109), an FDA-approved orally administered microbiome therapeutic, is indicated to prevent rCDI following antibiotics for rCDI.” PMID 38941068 ↗ Jun 2024 |
| Known as | VOWST | “VOWST (VOWST oral spores, VOS; fecal microbiota spores, live-brpk, formerly SER-109) is an FDA-approved, orally administered consortium of purified Firmicutes spores developed...” PMID 41491103 ↗ Jan 20261“VOWST oral spores (VOS, previously SER-109), an FDA-approved orally administered microbiome therapeutic, is indicated to prevent rCDI following antibiotics for rCDI.” PMID 38941068 ↗ Jun 2024 |
| Known as | VOWST oral spores | “VOWST (VOWST oral spores, VOS; fecal microbiota spores, live-brpk, formerly SER-109) is an FDA-approved, orally administered consortium of purified Firmicutes spores developed...” PMID 41491103 ↗ Jan 2026 |
| Modality | Other / unclassified | “SER-109, an investigational microbiome drug of donor-derived, purified spores, reduced recurrence in a dose-ranging, phase (P) 1 study in subjects with multiple rCDIs.” PMID 32255488 ↗ Jun 2021 |
| Route | Oral | “VOWST (VOWST oral spores, VOS; fecal microbiota spores, live-brpk, formerly SER-109) is an FDA-approved, orally administered consortium of purified Firmicutes spores developed...” PMID 41491103 ↗ Jan 2026 |